Letter to the EVE Editorial Board and Dr Bonilla, I enjoyed your clinical commentary in the March issue of EVE on equine bone cysts (Bonilla 2021); however, I am concerned with some of the text describing bisphosphonate use. The safety of bisphosphonates as a class of drug is a discussion that should be addressed through research upon which we both agree. Rather, it is the comment that 'Erratic bone healing is seen by surgeons around the world in horses that have received bisphosphonates during early age' which concerns me. The March EVE review (Skov Hansen et al. 2021) and commentary were predicated on the fact that it caused erratic healing in the Skov Hansen case; however, this horse was 10 years old and had reached equine skeletal maturity based on most anatomical standards, thus refuting the observational concerns with respect to bisphosphonate use "in young Thoroughbreds" or "early age" horses as identified by Dr. Bonilla and other surgeons.The class of bisphosphonates approved for use in horses in both Canada and the USA is for horses 4 years old and upwards. Health Canada and the CVM/FDA list no known causation or effect thereof on bisphosphonate use and 'erratic bone healing in young horses'. The open access adverse event report data from Health Canada and the FDA describe the roughly 234 cases of safety concerns with respect to bisphosphonates. Aereports.com provides this useful information to universities and pharmaceutical companies around the world where signal and causal relationships could pose safety risks. I have examined these data extensively for both Tiludronate and Clodronate and find no data to merit the commentary on young horses, bisphosphonates and erratic bone healing. I would kindly ask this comment be addressed in the next issue of EVE.As a racehorse owner and practicing veterinarian, I would like to see our vet colleagues educated on the full efficacy and safety profile of drugs. I would also urge the author and EVE editorial board to refrain from broad statements when publishing as this might be misconstrued by some to mean that bisphosphonates are inherently dangerous in horses of any age. Lastly, if in fact there are safety concerns on specific horse cases with administration of Tiludronate or Clodronate, I would encourage anyone to contact Health Canada or the FDA at the following numbers.FDA 1-888-FDA-VETS Health Canada 1-866-225-0709